Lymphocyte markers and prediction of long-term renal allograft acceptance

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 6, 2009, Pages 489-494

  Babel, Nina ^a,b   Reinke, Petra ^a,b   Volk, Hans Dieter ^b,c  

^a Department of Nephrology ^*  (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immune monitoring; Rejection; Tolerance; Transplantation

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; T LYMPHOCYTE RECEPTOR; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLIC DISORDER; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PREDICTION; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION TOLERANCE; VIRUS INFECTION; ALLOTRANSPLANTATION; ANIMAL; BLOOD; DRUG EFFECT; DRUG MONITORING; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PATIENT SELECTION; PREDICTION AND FORECASTING; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; BIOLOGICAL MARKERS; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 73349107808     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283318f82     Document Type: Review

References (58)

1. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001 ; 344:947-954. (Pubitemid 32240312)
2. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal allograft recipients. N Engl J Med 2005; 353:2342-2351. (Pubitemid 41713746)
3. + lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17:294-304.
4. Graziotto R, Del Prete D, Rigotti P, et al. Perforin, Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft rejection: analyses on serial biopsies suggest methodological issues. Transplantation 2006; 81:1125-1132.
5. Veale JL, Liang LW, Zhang Q, et al. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. Hum Immunol 2006; 67:777-786. (Pubitemid 44572593)
6. Homs S, Mansour H, Desvaux D, et al. Predominant Th 1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am J Transplant 2009; 9:1230-1236. This study demonstrates the role of T-cell mediated inflammatory/cytotoxic processes in the pathogenesis of transplant glomerulopathy.
7. Braudeau C, Racape M, Giral M, et al. Variation in numbers of CD4+CD25 high FOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transplant Int 2007; 20:845-855. (Pubitemid 47393535)
8. Mansour H, Homs S, Desvaux D, et al. Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol 2008; 19:2277-2281. This study suggests that Foxp3 mRNA exression is a useful predictive marker of borderline histologic changes in renal transplant patients.
9. Sawitzkl B, Bushell A, Steger U, et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007; 7:1091-1102. (Pubitemid 46643117)
10. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th 17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205:3133-3144. This is the first study demonstrating the role of TH 17 in the development of allograft rejection in the absence of Th1 -mediated alloimmunity.
11. Burrell BE, Csencsits K, Lu G, et al. CD8- Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deflcient mice. J Immunol 2008; 181:3906-3914.
12. Kotsch K, Mashreghl MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 2004; 77:1866-1875. (Pubitemid 38822210)
13. Avihingsanon Y, Ma N, Pavlakis M, et al. On the intraoperative molecular status of renal allografts aftervascular reperfusion and clinical outcomes. J Am Soc Nephrol 2005; 16:1542-1548. (Pubitemid 41716461)
14. Akalin E, Hendrix RC, Polavarapu RG, et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001; 72:948-953. (Pubitemid 32879872)
15. Lu BS, Yu AD, Zhu X, et al. Sequential gene expression profiling in lung transplant recipients with chronic rejection. Chest 2006; 130:847-854. (Pubitemid 44423619)
16. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349:125-138. (Pubitemid 36818782)
17. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5:330-340. (Pubitemid 40179520)
18. Martínez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance In liver transplant recipients. J Clin Invest 2008; 118:2845-2857. The data of the study demonstrate transcriptional profiling of peripheral blood that can be employed to identify liver transplant recipients appropriate for the discontinuation of immunosuppressive therapy.
19. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6:150-160.
20. Mehra MR, Kobashigawa JA, Deng MC, et al. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant 2008; 27:297-301.
21. This study applied a previously established transcriptional profile using 11 distinct genes for prediction of cardiac allograft rejection weeks to months prior to the actual event. The authors were able to separate patients early after transplantation into low-risk, intermediate-risk or high-risk categories for future rejection.
22. Braud C, Baeten D, Giral M, et al. Immunosuppressive drug-free operational immune tolerance In human kidney transplant recipients. Part I. Blood gene expression statistical analysis. J Cell Biochem 2008; 103:1681-1692.
23. This study demonstrates a unique peripheral blood mononuclear cell gene signature associated with human operational tolerance In kidney transplant patients using the expression pattern of 343 genes.
24. Visner GA, Goldfarb SB. Posttransplant monitoring of pediatric lung transplant recipients. Curr Opin Pediatr 2007; 19:321-326. (Pubitemid 46788120)
25. Zeevi A, Britz JA, Bentlejewskl CA, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005; 15:17-24. (Pubitemid 41435099)
26. Kowalski RJ, Zeevi A, Mannon RB, et al. Immunodiagnostics: evaluation of functional T-cell immnocompetence in whole blood independent of circulating cell numbers. J immunotoxlcol 2007; 4:225-232. (Pubitemid 47360098)
27. Israeli M, Yussim A, Mor E, et al. Preceeding the rejection: in search for a comprehensive posttransplant immune monitoring platform. Transpl Immunol 2007; 18:7-12. (Pubitemid 46920968)
28. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-g-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163:2267-2275. (Pubitemid 29382237)
29. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004; 4:648-655. (Pubitemid 39025050)
30. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3:878-884. (Pubitemid 36827910)
31. Näther BJ, Nickel P, Bold G, et al. Modified ELISPOT technique: highly significant inverse correlation of post-Tx donor-reactive IFN-γ-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl Immunol 2006; 16:232-237. (Pubitemid 44816482)
32. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-produclng cells identifies T-cell presensituation and correlates with graft function at 6 and 12 months in renaltransplant recipients. Transplantation 2004; 78:1640-1646. (Pubitemid 39648437)
33. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19:1419-1429.
34. This study demonstrates for the first time that circulating donor-specific alloreactive T cells primed by direct and indirect allorecognition pathways are detectable long after transplantation and are associated with graft injury.
35. Augustine JJ, Poggio ED, Clemente M, et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol 2007; 18:1602-1606. (Pubitemid 46729200)
36. Kim SH, Oh EJ, Kim MJ, et al. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc 2007; 39:3057-3060.
37. Reinsmoen NL, Cornett KMM, Kloehn R, et al. Pretransplant donor-specific and nonspecific immune parameters associated with early acute rejection. Transplantation 2008; 85:462-470. The data of the study showed that HLA class I mismatches, total HLA mismatches, pretransplant HLA-donor specific antibodies as well as higher pretransplant iATP levels were associated with biopsy-proven acute rejection.
38. Andree H, Nickel P, Nasiadko C, et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006; 17:573-580.
39. Poggio ED, Clemente M, Hricik DE, et al. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006; 17:564-572.
40. Van Besouw NM, Zuijderwujk JM, Vaessen LM, et al. The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation. Clin Exp Immunol 2005; 141:534-540.
41. Baker RJ, Hernandez-Fuentes MP, Brookes PA, et al. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167:7199-7206.
42. Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus coinfections in patients with CMV disease: correlation with clinical and virologie outcomes. Am J Transplant 2009; 9:374-381.
43. Babel N, Schwarzmann F, Prang N, et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001; 72:736-739. (Pubitemid 32802763)
44. Holmes MV, Caplin B, Atkinson C, et al. Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. Transplantation 2009; 87:852-856.
45. Babel N, Fendt J, Karaivanov S, et al. Sustained BK viruri a as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. Transplantation 2009; 88:89-95.
46. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1 -specific CD8 T cells. J Exp Med 2005; 201:1031-1036. (Pubitemid 40524670)
47. Sund F, Lidehäll AK, Claesson K, et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant 2009 [Epub ahead of print]
48. Egli A, Binet I, Binggel S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6:29. (Pubitemid 351891438)
49. Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1 -specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol 2009; 20:238-242.
50. Sato T, Fujieda M, Maeda A, et al. Monitoring of Epstein-Barr virus load and killer T cells In pediatric renal transplant recipients. Clin Nephrol 2008; 70:393-403.
51. Meij P, van Esser JWJ, Niesters HGM, et al. Impaired recovery of Epstein-Barr virus (EBV) specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high-risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101:4290-4297. (Pubitemid 36857791)
52. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007; 17:203-210. (Pubitemid 46304228)
53. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123-1131. (Pubitemid 47281407)
54. Savoldo B, Goss JA, Hammer M, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes. Blood 2006; 108:2942-2949. (Pubitemid 44776930)
55. Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008; 13:569-574.
56. Zhou W, Sharma M, Martinez J, et al. Functional characterization of BK virusspecific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol 2007; 20:379-388. (Pubitemid 47585319)
57. Hammer MH, Brestrich G, Andree H, et al. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant 2006; 6:625-631.
58. Aimeras C, Foulongne V, Garrigue V, et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 2008; 85:1099-1104. (Pubitemid 351590186)